Innovation and commercial development
The Frazer Institute is a modern research facility where clinical and basic science are used to study cancer, immunology and genomic medicine. The Institute has a vibrant community of over 300 researchers, students and support staff. We have delivered global, worldchanging discoveries such as:
- Discovery, development and release of the world’s first cervical cancer vaccine.
- Identification of genes responsible for one-third of the risk of developing ankylosing spondylitis.
- Development of a new test to identify patients with the potential to develop diabetes.
- Development of new ways of identifying melanoma.
- Identification of new markers for blood cancer.
- Identification of new genes involved in osteoporosis, birth weight and other complex genetic traits.
- Clinical trial for the world’s first rheumatoid arthritis treatment.
The Frazer Institute has a strong history of commercialising early-stage technologies and successfully translating these to the clinic.
Commercial activities undertaken at the Frazer Institute include:
- Intellectual property management
- Industry partnerships
- Development of a range of Frazer Institute technologies
For further information, please contact our Research Partnerships Manager or visit UniQuest.